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Abstract. Mild cognitive impairment (MCI) is a clinical concept proposed as an intermediate state between normal aging and
dementia. This condition has multiple heterogeneous sources, including clinical presentation, etiology, and prognosis. Recently,
the prevalence and associated features of neuropsychiatric symptoms (NPS) in MCI have been described. We systematically
searched the PubMed database (last accessed on August 31, 2008) for articles on NPS in MCI. Included articles used strict
selection criteria, and outcome variables were extracted in duplicate; of the 27 articles included, 14 (52%) used prospective
cohorts. The global prevalence of NPS in MCI ranged from 35% to 85%. The most common behavioral symptoms were
depression, anxiety, and irritability. Hospital-based samples reported a higher global prevalence of NPS than population-based
studies; this discrepancy probably reflected differences in demographics, study setting, MCI diagnostic criteria, and behavioral
instruments used. Prospective studies showed that NPS, particularly depression, may represent risk factors for MCI or predictors
for the conversion of MCI to Alzheimer’s disease (AD). NPS are very prevalent in subjects with MCI, displaying a similar pattern
of symptoms compared to dementia and AD. Large cohort studies using standardized MCI criteria and behavioral instruments
are required to evaluate the prognostic role of NPS in MCI.
Keywords: Alzheimer’s disease, behavior, dementia, depression, incidence, mild cognitive impairment, neuropsychiatric symp-
toms, predictors, prevalence, risk factors
INTRODUCTION
The clinical concept of mild cognitive impairment
(MCI) identifies subjects who are in an intermediate
state between normal aging and dementia [1–4]. MCI
∗Corresponding author: Roberto Monastero, MD, PhD, Labora-
tory of Epidemiology and Psychology of Aging and Dementia, Sec-
tion of Neurology, Department of Clinical Neuroscience, University
of Palermo, Via La Loggia 1, 90129 – Palermo, Italy. Tel.: +39
091 6555185; Fax: +39 091 6555113; E-mail: roberto.monastero
@unipa.it; roberto.monastero@ki.se.
is currently defined as a syndrome characterized by an
impairment of memory or other cognitive functions,
which does not have an effect on or slightly impairs
an individual’s instrumental functional abilities, in sub-
jects who have not been clinically diagnosed with de-
mentia [4]. MCI appears to be an extremely heteroge-
neous condition in terms of etiology, clinical presenta-
tion, and outcome [1,5]. The syndrome can be divid-
ed into two broad subtypes: an amnestic type (aMCI),
characterized by reduced memory functioning, and a
non-amnestic type (naMCI) in which cognitive func-
tions other than memory are impaired [3].
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While aMCI seems to represent an early stage of
Alzheimer’s disease (AD), the outcomes of naMCI ap-
pear to be more heterogeneous, and they include an
evolution toward vascular dementia,frontotemporal de-
mentia, and dementia with Lewy bodies [3]. However,
MCI is a syndrome of increased risk but not a prodro-
mal phase for impending dementia. Indeed, a signif-
icant rate of reversion from MCI to normal cognition
and functioning has been observed [6,7], thus suggest-
ing that an underlying, potential, reversible cause of
MCI could also be neuropsychiatric comorbidity, with
an inherent implication for treatment [8,9].
As is the case with dementia, neuropsychiatric symp-
toms (NPS) have not been included in the concept of
MCI and only recently have various studies described
the neuropsychiatric features of the condition [10].
NPS, which occurs in at least one-third of MCI sub-
jects [10], have been associated with worse cognitive
performance, functional disability, and mild extrapyra-
midal signs [11–14]. Furthermore, they have been pro-
posed as independent risk factors for the development
of MCI [15–18] as well as predictors of conversion
from MCI to dementia and AD [18–24]. However, the
prognostic role of NPS in MCI is still under debate.
In this systematic review, we summarize the current
evidence on NPS in MCI.
METHODS
Search strategy
All studies which included an assessment of NPS
in subjects with MCI were eligible for inclusion (see
below for details of criteria used). In order to identify
the articles, we systematically searched the PubMed,
National Library of Medicine database for English-
language articles (last accessed on August 31, 2008,
and including Epub reports). Furthermore, we found
additional papers by performing a manual search of
the reference lists of relevant retrieved articles, the ta-
bles of contents of relevant journals, and one previous
systematic review published on NPS in MCI [10].
We combined the results of searches in PubMed into
2 separate domains: 1) mild cognitive impairment [key-
word]; and 2) delusions, hallucination, psychomotor
agitation, aggression, depression, anxiety, euphoria,
irritable mood [MeSH Terms] or neuropsychiatric, be-
havioral and psychological symptoms, psychosis, delu-
sion, hallucination, agitation, aggression, depression,
anxiety, euphoria, apathy, disinhibition, irritability,
aberrant motor behavior and wandering [keywords].
Data extraction
A total of 461 articles were identified through
database searches. Studies were subsequently select-
ed for inclusion in our systematic review if they met
all of the following criteria: 1) the study had to in-
clude an MCI definition, which was not only based on
Mini-Mental State Examination [25] averages and/or
other global cognitive or clinical scales (e.g., Clinical
Dementia Rating scale – CDR) [26], but the definition
necessitated broader criteria, including specific cogni-
tive testing; 2) NPS had to be collected using standard-
ized instruments, excluding NPS obtained from sub-
jective reports; 3) regarding the descriptive epidemio-
logical features of NPS in MCI, the prevalence and/or
incidence rates of NPS had to be described in the text.
With regard to the associated factors of NPS in MCI,
the risk factors for MCI development or the conversion
from MCI to dementia, chi-square analysis, odds ra-
tios, relative risks or other measures of association had
to have been reported; and 4) the study had to include
a minimum MCI sample of 40.
The search was run in two phases. Firstly, the titles
and abstracts were read by two authors (C.C. and S.E.)
and, if we were uncertain about data from the title and
the abstract, the full study was obtained. A total of
429 articles were excluded, based on reviewing titles
and abstracts, thus leaving 32 reports for full review.
These totaled 39 papers because an additional seven
articles were identified in the manual search of refer-
ences. Secondly, data were extracted independently
by two investigators (R.M. and F.M.), using a struc-
tured proforma, including the following information:
study type (cross-sectional or longitudinal); study set-
ting (hospital-based, GP-based, clinical trial, clinico-
pathological study, population-based); number of MCI
subjects included at baseline; length of follow-up in
years; mean age of MCI samples; percentage of females
within the MCI groups; behavioral instruments used to
evaluate NPS; the MCI diagnostic criteria adopted and
subtypes included; excluded groups; and main find-
ings. The latter included the prevalence rates of NPS
in MCI and the associated factors for each NPS in MCI
in cross-sectional studies. Furthermore, the incidence
rates of NPS in MCI and the role of each NPS as a
putative risk factor for MCI or as predictors for the evo-
lution from MCI to dementia and AD in cohort studies
were examined. Original methodological articles be-
longing to prospective cohort studies, describing study
characteristics for MCI criteria and NPS assessment,
were evaluated if needed. Duplicate papers were also
R. Monastero et al. / A Systematic Review of NPS in MCI 13
Fig. 1. Flow diagram of search strategy and study selection.
sought. Disagreements were discussed and if consen-
sus was not reached, a third author (R.C.) was the final
arbitrator. Specifically, 33 out of 39 reviewed articles
were similarly judged by the two reviewers and the
inclusion of the remaining six papers was definitively
resolved by the final arbitrator. Using Cohen’s kappa
coefficient (a statistical measure of inter-rater agree-
ment for categorical data), the reliability in our selec-
tion process between the two reviewers was “almost
perfect” (kappa = 0.85), according to the Landis and
Kock interpretation of kappa values [27]. Overall, from
39 articles that were reviewed, only 27 were eligible
for inclusion (see Fig. 1). Two out of the six papers
judged by the final arbitrator were finally included in
the full review process, including 27 articles, while 4
were excluded.
Study design, sample size, demographics and
outcomes
The study characteristics are detailed in Table 1.
Briefly, of a total of 27 selected articles: 12 were
hospital-based studies (7 cross-sectional and 5 longitu-
dinal) [13,14,16,20–22,24,28–32]; 2 were multicenter
cross-sectional general practitioners studies [33,34]; 1
was from a large multicenter clinical trial [12]; 1 was a
clinicopathological study of older Catholic clergy per-
formed throughout the USA [35]; and there were 11
population-based studies (3 cross-sectional, 7 longitu-
dinal and 1 which reported both cross-sectional and
longitudinal data) [11,15,17–19,23,36–40].
The sample size for studies evaluating NPS in MCI
varied enormously within studies, ranging from 44 to
2,879 subjects at baseline; the median sample size was,
however, equal to 121 subjects. For longitudinal stud-
ies, the length of follow-up was similar, ranging from
a mean of 2.0 to 5.8 years. Mean age at baseline varied
within studies ranging from 65.2 to 80.6 years. Similar-
ly, the percentage of females included differed within
studies, ranging from 35% to 75%.
Of the 27 articles included in the systematic review
concerning outcomes, 9 described the descriptive epi-
demiological features of NPS in MCI (e.g., prevalence
and incidence rates) [12,29–34,36,40], while 14 re-
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ported the analytic epidemiological features of NPS in
MCI (e.g., associated factors for NPS in MCI, NPS as
risk factors for MCI development or as predictors for
MCI conversion to dementia) [13–18,20–22,24,28,35,
38,39]. Furthermore, the remaining 4 articles report-
ed both the descriptive and analytical epidemiological
features of NPS in MCI [11,19,23,37].
Diagnostic criteria for MCI, included subtypes and
excluded groups
Included studies adopted different sets of diagnos-
tic criteria for MCI (Table 2). Briefly, 4 studies [16,
22,30,37] used the original clinical criteria for aMCI
proposed by Petersen et al. [2], where a diagnosis of
MCI is made if the subjects met the following crite-
ria: 1) memory complaint (preferably corroborated by
a caregiver); 2) normal activities of daily living; 3) nor-
mal general cognitive function; 4) abnormal memory
on cognitive testing (generally performance  1.5 SD
below age and education-adjusted scores); and 5) the
absence of dementia (clinical judgment). Two addi-
tional studies [20,29] used Petersen’s criteria but also
included subjects with some minor impairment in the
non-memory domains in the aMCI group.
Nine studies [13–15,17,24,28,31,32,36] relied on
MCI modified criteria of Winblad and colleagues [4]
which includes: 1) evidence of cognitive decline, mea-
sured either by self and/or caregiver report, in conjunc-
tion with deficits on objective cognitive tasks, and/or
evidence of decline over time on objective neuropsy-
chological tests (generally performance  1.5 SD be-
low age and education-adjusted scores); 2) preserved
basic activities of daily living/minimal impairment in
complex instrumental functions; and 3) the absence of
dementia (clinical judgment). Four additional stud-
ies used Winblad’s criteria, adopting a different cut-
off point for rating cognitive decline (performance 
1.0 SD below or in the lower quartile range for age
and education-adjusted scores) [19,21,33,34]. One of
these four studies did not adopt the criteria of subjective
cognitive complaints [34].
Six population-based studies mainly used a neurop-
sychological-driven approach to define MCI subjects
with the adoption of different age- and education-
adjusted cut-off points after excluding dementia cas-
es [18,23,35,38–40]. Data from the clinical trial used a
combination of the New York University delayed para-
graph recall test and a CDR score of 0.5 [12]. Finally,
in one article, MCI was only classified by relying on
neuropsychological performance [11].
MCI has two main subtypes: aMCI, which is primar-
ily characterized by impaired memory with relatively
unimpaired or less-impaired functioning in other cogni-
tive domains; and naMCI, characterized by impairment
in one or more cognitive domains other than memory,
including language, attention, executive functioning,
etc. [3].
In brief, of the 27 selected articles included in this
review, there were 7 hospital-based studies which fo-
cused on aMCI [13,16,20–22,29,30] while 5 described
both aMCI and naMCI subjects [14,24,28,31,32]. In
the two multicenter cross-sectional GP studies [33,34],
the authors described data from aMCI in addition to
naMCI, while the multicenter clinical trial included on-
ly aMCI subjects [12]. The clinicopathological study
of older Catholic clergy included a sample of MCI
without detailing the type of cognitive impairment [35].
Regarding population-based studies, 4 articles includ-
ed aMCI subjects [37–40], 1 was both aMCI and naM-
CI [23], and 6 described the entire MCI group [11,15,
17–19,36]. Five out of these 6 included both aMCI and
naMCI [11,15,17,19,36] while one gave no details of
the type of cognitive impairment [18].
With reference to the excluded groups, the presence
of major depression was an exclusion criterion in 5
studies [12,13,20,29,37], and, in one of these, other
psychiatric disorders and those subjects receiving psy-
chotropic drugs in amounts affecting cognition were
also excluded [37]. In the international multicenter In-
vestigation in the Delay to Diagnosis of AD with Ex-
elon (InDDEX) trial [12], subjects with no, very mild,
or major depression were also excluded. Lastly, in the
studies by Geda and colleagues [16,30], subjects with
severe neurologic and psychiatric conditions interfer-
ing with cognitive assessment and persons receiving
psychotropic drugs in amounts affecting cognition were
excluded.
Behavioral instruments used
Studies included in this review have adopted several
different behavioral instruments for the evaluation of
NPS (Table 1), a brief description of which is outlined
in Table 3. Twelve studies out of 27 included in this
review used standardized instruments, assessing de-
pressive symptoms [13,15–17,21,28,33–35,38–40]; in
4 other cases information from depression scales were
corroborated using Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) [41] cri-
teria for major depression [19,20,22,29]. All adopted
depressive scales were developed or applicable to elder-
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Table 2
Neuropsychiatric symptoms in mild cognitive impairment: diagnostic criteria adopted, included subtypes, and excluded groups
Source MCI criteria MCI subtypes Excluded groups
[study reference] Subjective IADL Definition of cognitive MCI aMCI naMCI
cognitive impairment impairment (all)
complaints (slight)
Bruce, 2008 [28] Yes Yes aWinblad’s modified MCI
criteria [4]
+ + +
Gabryelewicz, Yes No bPetersen’s original MCI +◦ subjects with severe DSM-
2004 [29] criteria [2], but with im-
pairment in non-memory
domain
IV major depression
Gabryelewicz, Yes No Petersen’s original MCI +◦ subjects with severe DSM-
2007 [20] criteria [2], but with im-
pairment in non-memory
domain
IV major depression
Geda, 2004 [30] Yes No Petersen’s original MCI
criteria [2]
+ persons with severe neuro-
logic and psychiatric con-
ditions interfering with
cognitive assessment and
persons receiving psy-
chotropic drugs in amount
affecting cognition
Geda, 2006 [16] Yes No Petersen’s original MCI
criteria [2]
+ persons with severe neuro-
logic and psychiatric con-
ditions interfering with
cognitive assessment and
persons receiving psy-
chotropic drugs in amount
affecting cognition
Houde, 2008 [21] Yes Yes Winblad’s modified MCI
criteria [4]
(1.0 SD below AEAS on
standard memory tests)
+◦
Hudon, 2008 [13] Yes Yes Winblad’s modified MCI
criteria [4]
+◦ subjects with DSM-IV ma-
jor depression
Lopez, 2005 [31] NS Yes Winblad’s modified MCI
criteria [4]
+ +
Modrego and Yes No Petersen’s original MCI +
Ferrandez, 2004 [22] criteria [4]
Rozzini, 2008a [32] Yes Yes Winblad’s modified MCI + +
and Rozzini, 2008b [14] criteria [4]
Teng, 2007 [24] Yes Yes Winblad’s modified MCI
criteria [4]
+ +
Luck, 2007 [33] Yes/No Yes Winblad’s modified MCI
criteria [4]
(1.0 SD below AEAS on
standard cognitive tests)
+ +
Weyerer, 2003 [34] No Yes Winblad’s modified MCI
criteria [4]
(1.0 SD below AEAS on
standard cognitive tests)
+ +
Feldman, 2004 [12] No Yes impaired performance on
NYU delayed paragraph
recall, no dementia and
CDR = 0.5
+ subjects with no o very
mild depression as well as
DSM-IV major depression
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Table 2, continued
Source MCI criteria MCI subtypes Excluded groups
[study reference] Subjective IADL Definition of cognitive MCI aMCI naMCI
cognitive impairment impairment (all)
complaints (slight)
Wilson, 2008 [35] NS NS identified by the neuropsy-
chologist after the exam-
ining physician excluded
dementia
+
Artero, 2008 [19] Yes Yes Winblad’s modified MCI
criteria [4]
(cognitive performance in
the lower quartile range for
AEAS on standard cogni-
tive tests)
+∗
Barnes, 2006 [15] Yes/no Yes Winblad’s modified MCI
criteria [4]
+∗
Chan, 2003 [11] No No  1.5 SD on one test or
1 SD on two or more tests
below AEAS on standard
cognitive tests
+∗
Lopez, 2003 [17] Yes/No Yes Winblad’s modified MCI
criteria [4]
+∗
Lyketsos, 2002 [36] Yes/No Yes Winblad’s modified MCI
criteria [4]
+∗
Muangpaisan, 2008 [37] Yes No Petersen’s original MCI
criteria [2]
+ persons with DSM-IV ma-
jor depression or oth-
er psychiatric disorders
and those receiving psy-
chotropic drugs in amount
affecting cognition
Palmer, 2007 [23] Yes No  1.0 SD below AEAS
on standard cognitive tests
and no dementia
+ + +
Panza, 2008a [38] No Yes impaired memory perfor- +
Panza, 2008b [39] mance ( 10th percentile
and Solfrizzi, of the distribution of
2007 [40] AEAS after exclusion of
prevalent dementia cases at
entry)
Stepaniuk, 2008 [18] Yes NS physicians and neuropsy-
chologists independently
diagnosed the subjects af-
ter excluding dementia;
confirmed by a consensus
conference
+
Abbreviations: MCI, Mild Cognitive Impairment; IADL, Instrumental Activities of Daily Living; aMCI, amnestic MCI; naMCI, non-amnestic
MCI; +, MCI group included; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; SD, standard deviation; AEAS, age-
and education-adjusted scores; NS, not specified; NYU, New York University; CDR, Clinical Dementia Rating scale.
aIncludes: (1) cognitive decline (self and/or informant report and impairment on objective cognitive tasks and/or evidence of decline over time on
objective cognitive tasks), (2) preserved basic activities of daily living/minimal impairment in complex instrumental functions, (3) no dementia
(clinical judgement).
bIncludes: (1) memory complaint, (2) normal activities of daily living, (3) normal general cognitive function, (4) abnormal memory for age, and
(5) no dementia (clinical judgement).
For a and b, excluded were specified in the table, cognitive impairment generally implies performance  1.5 SD below AEAS on standard
cognitive tests.
*These groups include both aMCI and naMCI subjects. ◦Together with aMCI subjects, these groups also included multi-domain aMCI individuals.
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Table 3
Neuropsychiatric symptoms in mild cognitive impairment: behavioral instruments used
Use/ Instrument [reference] Rating Time taken (min)
Depression
BDI [43] self-rated 20
MADRS [44] by trained interviewer with subject 20
GDS [45] self-administered 5–10
CES-D [42] self-administered 5
Behavioral and psychological symptoms in demented subjects
NPI (10 behavioral symptoms: delusions, hallucinations, dysphoria,
anxiety, agitation, euphoria, disinhibition, irritability, apathy, aberrant
motor behavior) [47]
by clinician in interview with caregiver 10
BSRS (12 items assessing the following behavioral symptoms: social
interaction, hallucinations, delusions, wandering, hoarding, yelling or
cursing, sleep problems, emotional instability, problem urination, re-
sisting help with everyday activities, verbal perseveration and physical
aggression) [48]
by trained interviewer with caregiver 10–15
CERAD-BRSD (46 items assessing the following behavioral symptoms:
depressive features, psychotic features, defective self-regulation, irri-
tability/agitation, vegetative features, apathy, aggression and affective
lability) [49]
by trained interviewer with subject 20–30
Global measures of psychiatric symptomatology
MINI (a short structured diagnostic interview for the evaluation of DSM-
IV and ICD-10 psychiatric disorders, including mood disorders, anxiety
disorders, somatoform disorders, psychotic disorders, etc.) [52]
by trained interviewer with subject 15
CPRS (65 items covering a broad range of functional psychopathology
in psychotic, mood and neurotic disorders as well as somatic anxiety
symptoms) [50]
by trained interviewer with subject 50
*CAMDEX section H (collected information, enables a psychiatric di-
agnosis to be made: dementia, delirium depression, anxiety or phobic
disorder, paranoid or paraphrenic illness and other psychiatric disor-
der) [51]
by trained interviewer with carer 20
Abbreviations: BDI, Beck Depression Inventory; MADRS, Montgomery-Asberg Depression Rating Scale; GDS, Geriatric Depression Scale;
CES-D, Center for Epidemiological Studies Depression Scale; NPI, Neuropsychiatric Inventory; BSRS, Behavioral Symptom Rating Scale;
CERAD-BRSD, Consortium to Establish a Registry for Alzheimer’s Disease Behavioral Rating Scale for Dementia; MINI, Mini International
Neuropsychiatric Interview; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ICD-10, International Classification of
Diseases, 10th edition; CPRS, Comprehensive Psychopathological Rating Scale; CAMDEX, Cambridge Examination for Mental Disorders of
the Elderly. *This instrument is not a pure behavioral scale but it is a standardized interview for the diagnosis of mental disorders in the elderly
with special reference to dementia.
ly subjects [42–46]. The remaining 11 studies adopted
behavioral instruments, evaluating a broad variety of
NPS [11,12,14,18,23,24,30–32,36,37].
Some of these multidimensional instruments were
specifically developed for elderly subjects with cog-
nitive impairment [47–49], while others represented
global measures of psychiatric symptomatology [50–
52]. Of the comprehensive scales, the most common-
ly used (7 studies) was the Neuropsychiatric Inventory
(NPI) [47]. Overall, the majority of behavioral instru-
ments used were to be administered to the patient or
his/her caregiver or both [44,47–52] while others were
self-administered [42,43,45].
RESULTS
1. Prevalence of NPS in MCI
An analysis of selected articles has revealed that NPS
constitute very common clinical features in subjects
with MCI. Indeed, considering at least one NPS, data
from some of these studies produced prevalence rates
ranging from 35% to 85% in MCI patients (Table 4) [11,
12,30,32,36]. Similar to that previously described for
dementia and AD [53,54], the 5 studies investigating
the prevalence of NPS in MCI via the NPI demonstrat-
ed that three symptoms (depression, anxiety, and irri-
tability) consistently comprise the most common be-
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Table 4
Neuropsychiatric symptoms in mild cognitive impairment: prevalence rates reported
by the included studies
Symptom Study setting Prevalence, % Behavioral instrument
[study reference]
Any NPI symptom Hospital-based 35–85 NPI [30,32]
GPs NA
Clinical trial 59 NPI [12]
Population-based 43 NPI [36]
47 BSRS [11]
Depression Hospital-based 9–78 NPI [30,32]
53 CERAD-BRSD [31]
36 CES-D [22]
52 GDS [21]
27 (minor) DSM-IV [29]
8–20 (major) DSM-IV [22,29,31]
GPs 15 GDS [33]
Clinical trial 45 NPI [12]
Population-based 16–46 NPI [11,36,37]
36 CPRS [23]
16–40 CES-D [17,19]
63 GDS [40]
2.4 (major) DSM-IV [19]
Apathy Hospital-based 11–53 NPI [30,32]
40 CERAD-BRSD [31]
GPs NA
Clinical trial 32 NPI [12]
Population-based 12–15 NPI [36,37]
36 CPRS [23]
Anxiety Hospital-based 11–74 NPI [30,32]
49 CERAD-BRSD [31]
GPs NA
Clinical trial 45 NPI [12]
Population-based 10–53 NPI [36,37]
47 CPRS [23]
Delusions Hospital-based 2–14 NPI [30,32]
14 CERAD-BRSD [31]
GPs NA
Clinical trial 6 NPI [12]
Population-based 0–3 NPI [36,37]
Hallucinations Hospital-based 0–14 NPI [30,32]
4 CERAD-BRSD [31]
GPs NA
Clinical trial 2 NPI [12]
Population-based 1–9 NPI [36,37]
Agitation Hospital-based 4–45 NPI [30,32]
38 CERAD-BRSD [31]
GPs NA
Clinical trial 35 NPI [12]
Population-based 5–11 NPI [36,37]
25 BSRS [11]
Irritability Hospital-based 13–53 NPI [30,32]
36 CERAD-BRSD [31]
GPs NA
Clinical trial 44 NPI [12]
Population-based 15–30 NPI [36,37]
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Table 4, continued
Symptom Study setting Prevalence, % Behavioral instrument
[study reference]
Euphoria Hospital-based 0–9 NPI [30,32]
GPs NA
Clinical trial 5 NPI [12]
Population-based 1 NPI [36,37]
Disinhibition Hospital-based 2–3 NPI [30,32]
GPs NA
Clinical trial 10 NPI [12]
Population-based 3–7 NPI [36,37]
Aberrant motor behavior Hospital-based 4–15 NPI [30,32]
GPs NA
Clinical trial 8 NPI [12]
Population-based 1–4 NPI [36,37]
Abbreviations: NPI, Neuropsychiatric Inventory; NA, not available; BSRS, Behavioral
Symptom Rating Scale; CERAD-BRSD, Consortium to Establish a Registry for Alzheimer’s
Disease Behavioral Rating Scale for Dementia; CES-D, Center for Epidemiological Studies
Depression Scale; GDS, Geriatric Depression Scale; DSM-IV, Diagnostic and Statistical
Manual of Mental Disorders, 4th edition; CPRS, Comprehensive Psychopathological Rating
Scale.
havioral abnormalities in MCI [12,30,32,36,37]. The
fourth and the fifth most common symptoms were ap-
athy and agitation.
Hospital-based samples reported a higher global
mean prevalence of any NPS than population-based
studies (60% vs. 45% respectively). In particular, the
former [30,32] described higher prevalence of nearly
all NPS compared with the latter [36,37]. Data from the
InDDEX trial reported NPS prevalence figures similar
to those described by hospital-based studies [12].
With respect to NPS distribution in different MCI
subgroups, only one hospital-based study evaluated the
wide NPS spectrum in aMCI versus naMCI [32]. In this
article, which reported the highest frequency of nearly
all NPS described thus far, the authors demonstrated
that aMCI displayed a higher frequency of depression,
apathy, and irritability than naMCI, while the latter
presented with a higher frequency of delusions and
hallucinations than the former. Nevertheless, the two
groups significantly differed only for hallucinations.
a) Depression: Depression is the most studied NPS
in subjects with cognitive impairment, dementia, and
AD [53,54]. Previous data have shown that depressive
symptoms occurring more than 25 years prior to diag-
nosis are associated with an increased risk of devel-
oping AD, thereby suggesting that depression proba-
bly predisposes the brain to a later vulnerability to the
disease [55,56]. Six hospital-based studies, 2 GP arti-
cles, the InDDEX trial, and 7 population-based studies
have reported descriptive epidemiological features of
depression in MCI.
Hospital-based studies
The prevalence of depressive symptoms ranged from
9% to 78% in MCI subjects attending hospital-based
settings [21,22,29–32]. Five out of these 6 articles,
which described the prevalence of depression in MCI,
reported data collected in subjects attending memory
clinics [21,22,29,31,32]; in the sixth article data were
obtained from subjects receiving their routine medi-
cal care at the Mayo Clinic Division of Community
Internal Medicine, subsequently referred to the Mayo
Alzheimer’s Disease Center [30]. Therefore, the preva-
lence figures of depression in MCI subjects directly at-
tending memory clinics were higher than those reported
by the study at the Mayo Clinic. In particular, MCI sub-
jects directly attending memory clinics showed a preva-
lence of depressive symptoms ranging from 36% [22]
to 78% [32] compared to 9% observed by the study
of the Mayo Clinic [30]. This observed variability in
symptom prevalence can also be accounted for by dif-
ferences in MCI diagnostic criteria and the sensitivity
of the behavioral instruments used. A further potential
contributor to this discrepancy could be the exclusion
of subjects with severe psychiatric conditions or those
using psychotropic drugs from the sample identified by
the study at the Mayo Clinic [30].
Gabrielewicz and collaborators [29] conducted a fac-
tor analysis with a varimax rotation to analyze the item
scores from the Montgomery and Asberg Depression
Rating Scale (MADRS) [44] in subjects with MCI.
They found three partly independent depressive sub-
syndromes: one characterized by complaints about sad-
ness; one characterized by predominant tension, anx-
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iety, and concomitant vegetative symptoms; and one
with decreased psychomotor activity. Three studies al-
so described the prevalence figures of minor and major
depression in their MCI samples according to DSM-IV
criteria [22,29,31]. In particular, minor depression was
observed in 27% of subjects [29], while the prevalence
of major depressive episodes ranged from 8% to 20%
of cases [22,29,31].
GP studies
The prevalence of depression was reported by two
studies describing data from a large multicenter cross-
sectional GPs study conducted in Germany [33,34].
The study sample included 818 MCI subjects, and de-
pression was assessed by the Geriatric Depression Scale
(GDS) [45]. In one of these studies [33], the prevalence
of depression in MCI subjects was 13%. In a subse-
quent analysis of the same sample [34], the authors de-
tailed specific prevalence figures of depression among
different MCI subtypes. In particular, depression was
found in 16% of subjects with single-domain aMCI, 9%
with single-domain naMCI, 19% with multi-domain
aMCI and 18% with multi-domain naMCI.
Clinical trial and population based-studies
The InDDEX trial [12] described baseline data of
1,010 aMCI subjects evaluated using the NPI. The In-
DDEX trial systematically excluded subjects with no
or very mild depressive symptoms as well as those with
a DSM-IV diagnosis of major depression. The preva-
lence of depressive symptoms in the InDDEX trial was
over 45% [12].
Sixteen to 63% of MCI subjects were enrolled in
population-based studies characterized by depressive
symptoms [11,17,19,23,36,37,40]. The results were
somewhat different between the studies, probably due
to the use of different behavioral instruments to as-
sess depression. In particular, Solfrizzi et al. [40] de-
tailed the highest prevalence of depressive symptoms
among MCI subjects reported thus far from population-
based studies. Indeed, they observed depressive symp-
toms in 63% of their MCI subjects evaluated with
the GDS. One study also described that 2.4% of their
MCI sample suffered from current major depressive
episodes [19], which were assessed using the Major
Depressive Episode module of the Mini International
Neuropsychiatric Interview (MINI) [52], according to
DSM-IV criteria.
b) Apathy: Apathy has been reported as the most
frequent NPS in subjects with dementia and AD [53,
54]. It commonly starts with a mild dementia stage and
progressively increases in frequency with progressing
dementia [53]. Three hospital-based studies, the In-
DDEX trial and 3 population-based studies have de-
scribed the prevalence figures of apathy in MCI.
Hospital-based studies
Substantially similar prevalence estimates of apathy
in MCI subjects were reported in the studies of Lopez
et al. (40%) [31] and Rozzini et al. (53%) [32], despite
the use of different behavioral instruments to evaluate
the presence/absence of apathy. In contrast, the authors
in the Mayo Clinic study reported a rather low preva-
lence of apathy (11%) [30]; the potential reason for
this variability was described above (see section “De-
pression: Hospital-based studies”). In the Mayo Clinic
study, apathy was the second most common symptom
of MCI subjects [30], while it was the third most preva-
lent symptom after depression and anxiety in the two
other studies [31,32].
Clinical trial and population based-studies
The prevalence of apathy reported by the InDDEX
trial in MCI subjects assessed with the NPI was over
32% [12]. A similar figure was obtained by examining
population-based data from the Kungsholmen Project,
a Swedish population-based cohort study [23]. Indeed,
in this study the authors, using the Comprehensive Psy-
chiatric Rating Scale (CPRS) [50], reported motivation-
related symptoms in 36% of MCI subjects. In contrast,
data from two other NPI-based studies conducted at a
population level reported a prevalence figure of apathy
of MCI 15% [36,37]. Apathy was the second most
common behavioral symptom in MCI subjects in two
population-based studies [23,36], while it was fourth in
the InDDEX trial [12] and in a Thai community-based
study [37].
c) Anxiety: Anxiety has been reported as the third
most common NPS in subjects with AD after apathy
and depression [53]. However, as a behavioral symp-
tom, it is difficult to evaluate in the elderly as separating
a medical condition from the physical symptoms of an
anxiety disorder is rather difficult in old age [57]. Fur-
thermore, diagnosing anxiety in individuals with de-
mentia can be particularly complex, and, indeed, agi-
tation typical of dementia may be confused with anx-
iety [57]. Three hospital-based studies, the InDDEX
trial and 3 population-based studies have investigated
anxious symptoms in MCI.
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Hospital-based studies
There was a substantial discrepancy in the preva-
lence rates of anxiety reported by the 3 hospital-based
studies conducted on MCI subjects thus far [30–32].
Two NPI-based studies described rather different preva-
lence rates of anxiety in MCI: 11% in the article by
the Mayo Clinic [30] versus 74% in that by Rozzini
et al. [32]. Using the Consortium to Establish a Reg-
istry for Alzheimer’s Disease Behavioral Rating Scale
for Dementia (CERAD-BRSD) [49], Lopez and col-
leagues [31] diagnosed anxiety in 49% of their MCI
sample. Again, this discrepancy may be due to different
sampling methods, MCI diagnostic criteria, and behav-
ioral instruments used. Anxiety was the second most
common behavioral symptom among MCI subjects in
the 3 hospital-based studies, after depression [31,32]
and irritability [30] respectively.
Clinical trial and population based-studies
The InDDEX study reported a very high prevalence
of anxiety (45%) among subjects included in their large
clinical trial of MCI subjects [12]. With reference to
studies conducted at a population-level in subjects with
MCI, data from two NPI-based studies described anxi-
ety in 10% [36] and 53% [37] of their cohorts respec-
tively. Similar to the latter, the CPRS-based data from
the Kungsholmen Project reported a prevalence of anx-
iety of 47% among MCI subjects [23]. Of interest, anx-
iety was the most common behavioral symptom among
MCI subjects in two population-based studies [23,37],
while it was the second in the InDDEX trial [12] and
the fourth in the Cardiovascular Health Study’s (CHS)
Cognition Study [36], a large multicenter population-
based cohort study.
d) Delusions and hallucinations: Psychotic symp-
toms are common and persistent features in patients
with AD, leading to a faster rate of cognitive decline,
excess disability, and early institutionalization [58].
They were also described as independent risk factors
for cognitive impairment in non-demented subjects [5].
Three hospital-based studies, the InDDEX trial and
3 population-based studies have reported prevalence
rates of psychotic features in MCI.
Hospital-based studies
The two NPI-based studies described a very low fre-
quency of psychotic symptoms in MCI subjects, rang-
ing from 2% to 14% for delusions and 0% to 14% for
hallucinations [30,32]. Of interest, Rozzini and col-
leagues [32] observed a significantly higher frequency
of hallucinations in naMCI (23%) compared to aMCI
(4%). Using the CERAD-BRSD, Lopez et al. [31] re-
ported the prevalence of hallucinations and delusions
among their MCI subjects to be 4% and 14% respec-
tively.
Clinical trial and population based-studies
The InDDEX trial and two population-based studies
used the NPI to evaluate the frequency of delusions
and hallucinations in MCI subjects [12,36,37]. The
InDDEX study described frequency rates of 6% for
delusions and 2% for hallucinations [12]. The CHS
Cognition Study reported very low prevalence rates of
delusions (3%) and hallucinations (1%) in MCI sub-
jects [36]. Similarly, Muangpaisan et al. [37] identi-
fied prevalence rates of 0% for delusions and 9% for
hallucinations. Finally, Chan et al. [11] in a small
population-based study of 121 MCI subjects reported a
global prevalence of psychosis of 9% using the Behav-
ioral Symptom Rating Scale (BSRS) [48].
e) Agitation: Prevalence rates of agitation in MCI
were described by 3 hospital-based studies, the InD-
DEX trial, and 3 population-based studies. Despite the
use of different behavioral instruments, similar preva-
lence estimates of agitation in MCI subjects were re-
ported by the hospital-based studies of Lopez et al.
(38%) [31] and Rozzini et al. (45%) [32]. In contrast,
the authors in the Mayo Clinic study reported the low-
est prevalence of agitation (4%) described thus far in
MCI [30]; in the InDDEX trial the frequency of agi-
tation was 35% [12]. Prevalence rates of agitation, as
measured by the NPI among MCI subjects enrolled in
population-based studies, ranged from 5% in the ar-
ticle by Muangpaisan et al. [37] to 11% in the CHS
Cognition study [36]. Using the BSRS, the population-
based study by Chan et al. [11] found the prevalence of
agitation among MCI to be 25%.
f) Irritability: Three hospital-based studies, the In-
DDEX trial, and 2 population-based studies report-
ed prevalence figures of irritability in MCI. The two
hospital-based studies which used the NPI observed
prevalence rates of irritability ranging from 13% in the
Mayo Clinic study [30] to 53% in the article by Rozzini
et al. [32]. Using the CERAD-BRSD, Lopez and col-
leagues [31] found the frequency of irritability among
MCI to be 36%. The InDDEX trial reported the highest
prevalence of irritability (44%) described thus far in
MCI [12]. NPI-based studies conducted at a population
levels described prevalence rates of irritability among
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MCI subjects which ranged from 15% in the CHS Cog-
nition Study [36] to 30% in the article by Muangpaisan
et al. [37].
g) Euphoria, disinhibition and aberrant motor be-
havior: Two hospital-based studies, the InDDEX tri-
al, and 2 population-based studies, all using the NPI,
have detailed prevalence rates of euphoria, disinhibi-
tion, and aberrant motor behavior in MCI subjects. In
hospital-based studies the frequencies of euphoria, dis-
inhibition, and aberrant motor behavior were 0–10%,
2–3%, and 4–15% respectively [30,32], while the In-
DDEX trial reported the highest prevalence of these
three NPS described thus far in MCI [12]. Lastly, in
population-based MCI cohorts, the frequencies of eu-
phoria, disinhibition, and aberrant motor behavior were
1%, 3–7%, and 1–4% respectively [36,37].
2. Incidence of NPS in MCI
Only one study has reported incidence figures of
NPS in subjects with MCI. In particular, Solfrizzi and
colleagues [40] described incidence rates of depressive
symptoms in MCI subjects enrolled in the Italian Lon-
gitudinal Study on Aging (ILSA) and prospectively fol-
lowed during a 3.5-year period using the GDS. Thirty-
six out of the 139 baseline MCI subjects were exam-
ined at follow-up for possible new onset of depressive
symptoms. During the 3.5-year follow-up period, all
36 MCI subjects developed a new onset of depressive
symptoms, with an estimated incidence rate of 29.6 per
100 person-years. No socio-demographic variables or
vascular risk factors modified the incidence of depres-
sive symptoms in cognitively stable MCI patients or in
MCI patients who reverted to normal cognition.
3. Associated factors of NPS in MCI
Three hospital-based studies, the InDDEX trial,
and 2 population-based studies described the cross-
sectional, associated factors of NPS in MCI. Rozzini et
al. [14] used data from 150 MCI outpatients to estab-
lish whether NPS are associated with mild parkinsonian
signs. The authors used the Unified Parkinson Disease
Rating Scale-motor section [59] to define the presence
of mild parkinsonian signs, while NPS were evaluated
using the NPI. The MCI group with mild parkinsonian
signs had a significantly higher prevalence of depres-
sion, apathy, and anxiety compared to the MCI group
not characterized by parkinsonian signs.
Hudon and collaborators [13] examined executive as
well as memory functioning in 44 subjects with aMCI,
referred to an outpatient memory clinic. The aMCI
subjects were distinguished according to the presence
or absence of subclinical depressive symptoms using
the GDS. Compared to the non-depressed aMCI group,
the depressed aMCI group displayed impaired execu-
tive functions, while the two groups did not substantial-
ly differ with regard to their verbal episodic memory.
In another hospital-based study, Bruce et al. [28] ex-
plored the relationship between cognitive functioning
and self-reported depression in 82 subjects with MCI
evaluated with the Beck Depression Inventory [43].
They found that poorer memory functioning was asso-
ciated with fewer self-reported depressive symptoms.
In addition, aMCI reported fewer symptoms of depres-
sion than naMCI subjects. The authors hypothesized,
consistent with that observed in AD patients [60], that
subjects with MCI may have difficulty reporting their
psychiatric symptoms due to problems of recall.
The association between NPS and cognitive func-
tioning was also evidenced by the InDDEX trial [12].
In this study subjects scoring  1 on the NPI had sig-
nificantly lower scores on measures of global cogni-
tion compared to subjects without NPS. Furthermore,
the former reported lower scores on functional mea-
sures than the latter. The association between function-
al difficulties and NPS in MCI was also reported by the
population-based study by Chan et al. [11]. After mul-
tivariate logistic regression analysis, the authors found
that the presence of any NPS symptoms, assessed us-
ing the BSRS, was significantly associated with dif-
ficulties in basic as well in the instrumental activities
of daily living. Another small population-based study
was conducted on the Thai population to investigate the
pattern of NPS in 77 MCI subjects and the influence
of socio-demographic factors on these symptoms [37].
The authors found that depression and anxiety, evalu-
ated using the NPI, were associated with self-reporting
of belonging to a low-status economic group.
4. NPS as risk factors/predictors for MCI and
conversion to dementia and AD
Thirteen studies evaluated the role of NPS as puta-
tive risk factors for MCI or as predictors for the conver-
sion from MCI to dementia and AD, using prospective
cohort studies. In particular, 5 hospital-based studies,
the clinicopathological study of older Catholic clergy,
and 7 population-based studies addressed this issue. 11
out of these 13 articles evaluated depression as a risk
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factor/predictor for MCI or its development to demen-
tia [15–22,35,38,39], one reported that anxiety symp-
toms predict conversion from MCI to AD [23], and the
latter found depression and apathy were more common
in subjects who were later diagnosed with AD [24].
With reference to hospital-based studies, Modrego
and Ferra´ndez [22] followed a cohort of 114 aMCI sub-
jects over a mean period of 3 years. At baseline exami-
nation, depression evaluated by the GDS was observed
in 36% of subjects. After a mean period of 3 years
depressed MCI were 2.6 times more likely to devel-
op dementia in comparison with non-depressed MCI.
Of interest, the survival analysis showed that depres-
sion predicts a faster cognitive deterioration in MCI
subjects. Furthermore, a poor response to antidepres-
sant therapy was seen in converters compared to non-
converters, thus suggesting that depression secondary
to AD pathology is persistent and possibly refracto-
ry to therapy. Gabryelewicz and colleagues [20] as-
sessed 105 patients with MCI over 3 years to investi-
gate the risk of the conversion of single aMCI versus
multiple-domain aMCI to dementia and to identify if
depression predicts this conversion. The authors found
that 22% of MCI patients developed dementia and that
depressive symptoms at baseline, as evaluated by the
MADRS, predicted a greater risk for developing de-
mentia. Houde et al. [21] evaluated 60 aMCI subjects
attending a memory clinic using the GDS for an av-
erage period of 4.3 years. They found that the sim-
ple presence or absence of depression at referral did
not predict the progression of MCI to AD. In contrast,
the positive answers to specific GDS items (i.e., those
related to melancholic depressive features) as well as
the persistence of depression over two to three years
significantly predicted conversion from MCI to AD.
In another large hospital-based, prospective cohort
study, Geda et al. [16] reported a synergistic interaction
between the apolipoprotein E4 (ApoE4) genotype and
depression in increasing the risk of aMCI. They fol-
lowed 840 initially cognitively normal and depression-
free individuals over a median of 3.5 years and found
that those who developed depression experienced dou-
ble the risk of subsequently developing aMCI. Those
subjects, who had recently developed depression (i.e.,
no past medical history of depressive episodes), dis-
played a hazard ratio (HR) for cognitive decline of 4.5
(95% confidence intervals [CI], 1.9–10.9), compared
to those who were never depressed. This suggests a
protective effect of antidepressant medications in sub-
jects with a previous history of depression. There was
an additive interaction between depression and ApoE4
in increasing the risk of developing aMCI (HR, 5.1;
95% CI, 1.9–13.6). In the study by Teng and collab-
orators [24], the authors evaluated NPS using the NPI
in 51 subjects with aMCI and naMCI attending mem-
ory clinics. Over a mean 2.0 years of follow-up, they
found that depression (67 vs. 31%) and apathy (50 vs.
18%) were significantly more common in MCI sub-
jects who were later diagnosed with AD, suggesting
that some NPS may be independently associated with
the progression from MCI to AD.
Several population-based studies confirmed the role
of NPS, particularly depression, as a risk factor for
MCI or its conversion to dementia. Lopez et al. [17]
examined risk factors for the development of MCI over
a mean period of 5.8 years in 2,895 participants of the
CHS Cognition Study. Of the several risk factors inves-
tigated, depressive symptoms – which were evaluated
using the Center for Epidemiological Studies Depres-
sion Scale (CES-D) [42] – were significantly associat-
ed with the development of MCI (Odds ratio [OR],1.5;
95% CI, 1.2–2.0). Another study used data from the
CHS Cognition Study to establish whether depressive
symptoms at baseline predicted an increased risk of
MCI over 6 years [15]. Depression, as evaluated by
the CES-D, was associated with an increased risk of
MCI, and this was correlated with the severity of base-
line depression. Interestingly, adjusting for several vas-
cular diseases (including carotid artery atherosclerosis
measured using duplex ultrasonography and cerebral
infarcts and white matter disease evaluated by magnet-
ic resonance imaging) had little effect, suggesting that
this association was independent of the presence of any
underlying vascular disease.
The Three City Study [19], a multi-site prospective
cohort study of community-dwelling people conduct-
ed in three French cities, examined 6,892 participants
of which 2,879 were diagnosed with MCI at baseline
during a 4-year period; depression was assessed by the
CES-D. The study reported that subclinical depression
was independently associated with the progression of
MCI to dementia only in women (OR, 2.0; 95% CI,
1.1–3.6), suggesting that the two sexes possess dif-
ferent risk profiles for this conversion. In the study
by the Kungsholmen Project [23], the role of mood-,
motivation- and anxiety-related symptoms were evalu-
ated in 47 MCI subjects who were followed for a mean
of 3 years as predictors for the progression from MCI
to AD. They found that the 3-year risk of progression
to AD almost doubled with each anxiety symptoms in
subjects with MCI (relative risk [RR], 1.8; 95% CI,
1.2–2.7). In contrast, mood-related symptoms predict
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conversion to AD in cognitively-intact subjects (RR,
1.9; 95% CI, 1.0–3.6). Accordingly, the authors sug-
gested that anxiety symptoms in MCI may represent
a subjective reaction to the initial phase of cognitive
deterioration, while mood-related symptoms may be
related to AD pathology, thus representing preclinical
signs of the disease. Another study, which analyzed da-
ta from the Canadian Study of Health and Aging [18],
evaluated the role of NPS as predictors for the conver-
sion from normal cognition to MCI as well as for the
progression from MCI to dementia and AD. A nation-
wide population-based study was used in which data
were collected 3 times at 5-year intervals; NPS were
evaluated using section H of the Cambridge Examina-
tion for Mental Disorders of the Elderly [51]. When
checking for initial cognitive status, loss of interest and
depression significantly contributed to the prediction of
MCI, dementia, and AD.
In contrast to the aforementioned data, three stud-
ies did not report depression as a risk factor for AD
or a predictor for its conversion to dementia and AD.
The Religious Order Study [35], a clinicopathologi-
cal study of older Catholic clergy, followed 917 older
Catholic nuns, priest, and monks without dementia at
study entry for up to 13 years, who were then evaluat-
ed annually; depression was evaluated with the CES-
D scale. Trajectories of depressive symptoms prior to
(mean follow-up of 3.2 years) and after (mean follow-
up of 3.9 years) the development of incident MCI were
estimated. There was no systematic change in depres-
sive symptoms before or after the initial MCI diagno-
sis, thus suggesting the depressive symptoms do not
increase in the prodromal phase of AD.
Similarly, data from the ILSA study suggested that
depressive symptoms, evaluated using the GDS, repre-
sent neither a risk factor for incident MCI nor predic-
tors for its progression to dementia [38,39]. As previ-
ously mentioned, these differences may be due to the
different enrollment criteria for the MCI cohort.
DISCUSSION
Our systematic review of previously published data
has revealed that NPS are very prevalent in subjects
with MCI. They may represent risk factors for MCI or
predictors for the conversion of MCI to dementia and
AD. According to these data, we believe it is impor-
tant to recognize and treat NPS early on in subjects
with MCI because this comorbidity can be associated
with worse cognitive performance, mild extrapyrami-
dal signs, and functional disability [11–14].
Concerning descriptive epidemiological features, the
global prevalence of NPS in MCI ranges from 35% to
85% [11,12,30,32,36], with a similar pattern of symp-
toms, albeit with reduced frequency, compared to de-
mentia and AD [53,54]. In particular, the most com-
mon behavioral symptoms are (in order of frequen-
cy): depression, anxiety, irritability, apathy, and agita-
tion, while less frequent symptoms are euphoria, dis-
inhibition, delusions, and hallucinations [12,30,32,36,
37]. Hospital-based samples [30,32] described a higher
global prevalence of NPS than population-based stud-
ies [36,37], probably reflecting selection bias (i.e., per-
sons attending memory clinics tend to report NPS with
higher frequency because their own symptomatology
is more serious than subjects evaluated at a population
level).
Only one hospital-based study has evaluated the wide
NPS spectrum in aMCI versus naMCI [32]. Subjects
with aMCI presented with higher frequency mood-
related features (i.e., depression and apathy) and irri-
tability than naMCI; in contrast, the latter displayed
more numerous psychotic-related features (i.e., delu-
sions and hallucinations) than the former. If confirmed,
this differential behavioral profile of aMCI versus naM-
CI subjects may be valuable in offering prognostic in-
formation as there is preliminary evidence that the two
conditions display differing outcomes [1,3]. There has
been a single study reporting the incidence figures of
NPS in MCI [40]. Over a 3.5 year follow-up period,
the authors estimated an incidence rate of depressive
symptoms of 29.6 per 100 person-years. Incidence
rates of depressive symptoms were not modified by
sociodemographic variables or vascular risk factors.
Differences in the prevalence of NPS between data
reviewed in this study may depend upon several fac-
tors. Firstly, differences in study setting (hospital vs.
population study) may have led to a selection bias. Sec-
ondly, differences in age and sex distribution within the
studies may have also caused differences in reported
prevalence figures. Indeed, it has been reported that
the prevalence of depression increases with age in cog-
nitively impaired subjects [9] and its related features
(i.e., mood- versus motivation-related symptoms) vary
with sex in the elderly [61], being higher in females
than in males. Thirdly, inclusion and exclusion crite-
ria may have affected reported prevalence figures. For
example, using  1.0 SD versus  1.5 SD below age
and education-adjusted scores as cut-off points for di-
agnosing cognitive impairment may have led to an in-
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crease in the size of MCI in a specific cohort. How-
ever, this group will probably possess less cognitive
deficits compared to those cohorts using the 1.5 SD
cut-off point with inherent reflections on the prevalence
of NPS. Regarding exclusion criteria, the exclusion of
subjects with depressive symptoms or those using psy-
chotropic drugs [12,13,16,20,29,30,37] may have af-
fected the prevalence not only of depression itself but
also of other comorbid NPS, due to the fact that the
former is often comorbid with the latter (e.g., apathy
and anxiety) [62,63].
Lastly, discrepancies in prevalence rates between
studies may be due to the differential sensitivity of
instruments used for evaluating NPS in MCI. Indeed,
various instruments have been specifically developed
to evaluate behavioral and psychological symptoms in
subjects with cognitive impairment and dementia (e.g.,
NPI, BSRS) [47,48], while others represent global mea-
sures of psychiatric symptomatology, developed for
adults and then applied to elderly subjects (e.g., CPRS,
MINI) [50,52]. Furthermore, subjects with MCI-
developing-dementia may have various mild problems
of insight, memory, and verbal expression, causing dif-
ficulty in providing reliable self-report information re-
lating to their behavioral profile [60]. Thus, the use of
a caregiver report to assess a subject’s behavioral status
often provides more information [64].
With reference to analytic epidemiological features,
NPS in MCI are associated with worsening cogni-
tive performance [12,13], functional disability [11,12],
mild extrapyramidal signs [14], and poor economic sta-
tus [37]. Furthermore, depression is associated with an
increased risk of developing MCI [15–18]. Of interest,
Geda and colleagues [16] have described a synergistic
interaction between depression and the ApoE4 geno-
type in increasing this risk, thus suggesting that depres-
sion could lead to cognitive impairment in the presence
of a specific genetic susceptibility factor. Lastly, base-
line levels of depression, apathy and anxiety were also
associated with an increased risk of conversion from
MCI to dementia and AD [18–24]. Notably, data from
one of these studies revealed that MCI subjects with a
poor response to antidepressant therapy are at increased
risk of developing dementia [22]. Globally, these data
suggest that NPS in MCI subjects could serve as clin-
ical indicators for the presence of prodromal demen-
tia; the lack of responsiveness to antidepressant treat-
ment strengthens this issue [22]. In contrast, recent
data from a clinicopathological study of older Catholic
clergy [35] as well as those by the ILSA study [38,
39] did not report depressive symptoms as a risk factor
for MCI or as a predictor for progression from MCI to
dementia. Contrasting findings between these studies
and data reported above can probably be accounted for
by differences in study setting, demographics, MCI di-
agnostic criteria, and the sensitivity of the behavioral
instruments used.
The strengths of this systematic review are the use of
strict inclusion criteria for study selection in attempting
to limit the heterogeneity of analyzed data. Further-
more, we used standardized procedures for extracting
data from included studies. However, various method-
ological issues deserve mentioning: first, we only eval-
uated studies in English; and second, the heterogeneity
in the population study settings, diagnostic criteria for
MCI, and various instrument for NPS assessment af-
fected our ability to compare data from different stud-
ies. One previous systematic review relating to this top-
ic has recently been published [10]. However, it sum-
marizes findings published before December 2006, it
used neither strict inclusion criteria for MCI diagnosis
nor did it address duplicate publication.
Overall, it seems clear that NPS and MCI often co-
occur in the elderly, and that mood-related and anx-
iety symptoms are frequently prodromal to MCI and
dementia. Since neuropathological signs of cognitive
impairment and dementia precede clinical symptoms
by many years [65,66], the direction of causality is not
clear: NPS may reflect specific pathological changes in
the brain or indicate a subjective reaction to cognitive
changes. Furthermore, in some cases NPS can mask the
detection of true MCI, while only reflecting the pres-
ence of an underlying behavioral disorder rather than
the product of a dementia-related illness. This kind
of psychogenic MCI could at least partly justify the
significant rate of reversion from MCI to normal cog-
nition and functioning, observed by population-based
studies [6,7]. Accordingly, the clinician must endeavor
to distinguish primary behavioral changes from cogni-
tive impairment, by firstly attempting to initiate specific
treatment for mood changes then, possibly, evaluating
and treating the cognitive disorder.
This review reveals that NPS are highly prevalent in
MCI. Furthermore, NPS increase the risk of developing
MCI and/or its future conversion to dementia. Due to
the highly heterogeneous data on NPS in MCI to date,
large cohort studies using standardized MCI criteria
and behavioral instruments are required to evaluate the
prognostic role of NPS in MCI; within this context sub-
jects with depression at baseline should not be exclud-
ed. Recently proposed directions for future research
on this issue include [9]: evaluating the prevalence,
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correlates and predictive validity of NPS in different
MCI subtypes; refining and developing approaches to
specifically assessing NPS in subjects with MCI; and
identifying genetic and biological markers linking NPS
to MCI and dementia. Lastly, the role of vascular risk
factors in mediating the relationship between NPS and
MCI should be detailed [67]. Taking these factors into
consideration, all this information would make a sig-
nificant contribution to enhancing treatment strategies
for subjects with MCI.
ACKNOWLEDGMENTS
The authors wish to thank J.O. Davies for the English
revision of the manuscript.
Authors’ disclosures available online (http://www.j-
alz.com/disclosures/view.php?id=44).
REFERENCES
[1] Mariani E, Monastero R, Mecocci P (2007) Mild cognitive
impairment: a systematic review. J Alzheimers Dis 12, 23-35.
[2] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG,
Kokmen E (1999) Mild cognitive impairment: clinical char-
acterization and outcome. Arch Neurol 56, 303-308.
[3] Petersen RC (2004) Mild cognitive impairment as a diagnostic
entity. J Intern Med 256, 183-194.
[4] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L,
Wahlund LO, Nordberg A, Ba¨ckman L, Albert M, Almkvist
O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erk-
injuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A,
Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild
cognitive impairment-beyond controversies, towards a con-
sensus: report of the International Working Group on Mild
Cognitive Impairment. J Intern Med 256, 240-246.
[5] Monastero R, Palmer K, Qiu C, Winblad B, Fratiglioni L
(2007) Heterogeneity in risk factors for cognitive impairment,
no dementia: population-based longitudinal study from the
Kungsholmen Project. Am J Geriatr Psychiatry 15, 60-69.
[6] Palmer K, Wang HX, Ba¨ckman L, Winblad B, Fratiglioni
L (2002) Differential evolution of cognitive impairment in
nondemented older persons: results from the Kungsholmen
Project. Am J Psychiatry 159, 436-442.
[7] Ritchie K, Artero S, Touchon J (2001) Classification criteria
for mild cognitive impairment: a population-based validation
study. Neurology 56, 37–42.
[8] Rosenberg PB, Johnston D, Lyketsos CG (2006) A clinical
approach to mild cognitive impairment. Am J Psychiatry 163,
1884-1890.
[9] Steffens DC, Otey E, Alexopoulos GS, Butters MA, Cuthbert
B, Ganguli M, Geda YE, Hendrie HC, Krishnan RR, Kumar
A, Lopez OL, Lyketsos CG, Mast BT, Morris JC, Norton MC,
Peavy GM, Petersen RC, Reynolds CF, Salloway S, Welsh-
Bohmer KA, Yesavage J (2006) Perspectives on depression,
mild cognitive impairment, and cognitive decline. Arch Gen
Psychiatry 63, 130-138.
[10] Apostolova LG, Cummings JL (2008) Neuropsychiatric man-
ifestations in mild cognitive impairment: a systematic review
of the literature. Dement Geriatr Cogn Disord 25, 115-126.
[11] Chan DC, Kasper JD, Black BS, Rabins PV (2003) Preva-
lence and correlates of behavioral and psychiatric symptoms
in community-dwelling elders with dementia or mild cogni-
tive impairment: the Memory and Medical Care Study. Int J
Geriatr Psychiatry 18, 174-182.
[12] Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink
P, Mancione L, Tekin S, Lane R, Ferris S (2004) Behavioral
symptoms in mild cognitive impairment. Neurology 62, 1199-
1201.
[13] Hudon C, Belleville S, Gauthier S (2008) The association
between depressive and cognitive symptoms in amnestic mild
cognitive impairment. Int Psychogeriatr 20, 710-723.
[14] Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Tra-
bucchi M, Padovani A (2008b) Mild parkinsonian signs and
psycho-behavioral symptoms in subjects with mild cognitive
impairment. Int Psychogeriatr 20, 86-95.
[15] Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD,
Yaffe K (2006) Depressive symptoms, vascular disease, and
mild cognitive impairment: findings from the Cardiovascular
Health Study. Arch Gen Psychiatry 63, 273-279.
[16] Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE,
Negash S, Boeve BF, Ivnik RJ, Petersen RC, Pankratz VS,
Rocca WA (2006) Depression, apolipoprotein E genotype, and
the incidence of mild cognitive impairment: a prospective
cohort study. Arch Neurol 63, 435-440.
[17] Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST,
Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carl-
son M, Kuller LH (2003) Risk factors for mild cognitive im-
pairment in the Cardiovascular Health Study Cognition Study:
part 2. Arch Neurol 60, 1394-1399.
[18] Stepaniuk J, Ritchie LJ, Tuokko H (2008) Neuropsychiatric
impairments as predictors of mild cognitive impairment, de-
mentia, and Alzheimer’s disease. Am J Alzheimers Dis Other
Demen 23, 326-333.
[19] Artero S, Ancelin ML, Portet F, Dupuy A, Berr C, Dartigues
JF, Tzourio C, Rouaud O, Poncet M, Pasquier F, Auriacombe
S, Touchon J, Ritchie K (2008) Risk profiles for mild cognitive
impairment and progression to dementia are gender specific.
J Neurol Neurosurg Psychiatry 79, 979-984.
[20] Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pf-
effer A, Androsiuk W, Chodakowska-Zebrowska M, Wasiak
B, Peplonska B, Barcikowska M (2007) The rate of conversion
of mild cognitive impairment to dementia: predictive role of
depression. Int J Geriatr Psychiatry 22, 563-567.
[21] Houde M, Bergman H, Whitehead V, Chertkow H (2008) A
predictive depression pattern in mild cognitive impairment. Int
J Geriatr Psychiatry 23, 1028-1033.
[22] Modrego PJ, Ferra´ndez J (2004) Depression in patients with
mild cognitive impairment increases the risk of developing
dementia of Alzheimer type: a prospective cohort study. Arch
Neurol 61, 1290-1293.
[23] Palmer K, Berger AK, Monastero R, Winblad B, Ba¨ckman
L, Fratiglioni L (2007) Predictors of progression from mild
cognitive impairment to Alzheimer disease. Neurology 68,
1596-1602.
[24] Teng E, Lu PH, Cummings JL (2007) Neuropsychiatric symp-
toms are associated with progression from mild cognitive im-
pairment to Alzheimer’s disease. Dement Geriatr Cogn Disord
24, 253-259.
R. Monastero et al. / A Systematic Review of NPS in MCI 29
[25] Folstein M, Folstein S, McHugh PR (1975) Mini-mental state:
a practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res 12, 189–198.
[26] Morris JC (1993) The Clinical Dementia Rating (CDR): cur-
rent version and scoring rules. Neurology 43, 2412–2414.
[27] Landis JR, Koch GG (1977) The measurement of observer
agreement for categorical data. Biometrics 33, 159–174.
[28] Bruce JM, Bhalla R, Westervelt HJ, Davis J, Williams V,
Tremont G (2008) Neuropsychological correlates of self-
reported depression and self-reported cognition among pa-
tients with mild cognitive impairment. J Geriatr Psychiatry
Neurol 21, 34-40.
[29] Gabryelewicz T, Styczynska M, Pfeffer A, Wasiak B, Bar-
czak A, Luczywek E, Androsiuk W, Barcikowska M (2004)
Prevalence of major and minor depression in elderly persons
with mild cognitive impairment-MADRS factor analysis. Int
J Geriatr Psychiatry 19, 1168-1172.
[30] Geda YE, Smith GE, Knopman DS, Boeve BF, Tangalos EG,
Ivnik RJ, Mrazek DA, Edland SD, Petersen RC (2004) De
novo genesis of neuropsychiatric symptoms in mild cognitive
impairment (MCI). Int Psychogeriatr 16, 51-60.
[31] Lopez OL, Becker JT, Sweet RA (2005) Non-cognitive symp-
toms in mild cognitive impairment subjects. Neurocase 11,
65-71.
[32] Rozzini L, Vicini Chilovi B, Conti M, Delrio I, Borroni B,
Trabucchi M, Padovani A. (2008a) Neuropsychiatric symp-
toms in amnestic and nonamnestic mild cognitive impairment.
Dement Geriatr Cogn Disord 25, 32-36.
[33] Luck T, Riedel-Heller SG, Kaduszkiewicz H, Bickel H, Jessen
F, Pentzek M, Wiese B, Koelsch H, van den Bussche H, Abholz
HH, Moesch E, Gorfer S, Angermeyer MC, Maier W, Wey-
erer S; AgeCoDe group (2007) Mild cognitive impairment in
general practice: age-specific prevalence and correlate results
from the German study on ageing, cognition and dementia
in primary care patients (AgeCoDe). Dement Geriatr Cogn
Disord 24, 307-316.
[34] Weyerer S, Eifflaender-Gorfer S, Ko¨hler L, Jessen F, Maier W,
Fuchs A, Pentzek M, Kaduszkiewicz H, Bachmann C, Anger-
meyer MC, Luppa M, Wiese B, Mo¨sch E, Bickel H; German
AgeCoDe Study group (German Study on Ageing, Cognition
and Dementia in Primary Care Patients) (2008) Prevalence and
risk factors for depression in non-demented primary care at-
tenders aged 75 years and older. J Affect Disord 111, 153-163.
[35] Wilson RS, Arnold SE, Beck TL, Bienias JL, Bennett DA
(2008) Change in depressive symptoms during the prodromal
phase of Alzheimer disease. Arch Gen Psychiatry 65, 439-445.
[36] Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J,
DeKosky S (2002) Prevalence of neuropsychiatric symptoms
in dementia and mild cognitive impairment: results from the
cardiovascular health study. JAMA 288, 1475-1483.
[37] Muangpaisan W, Intalapaporn S, Assantachai P (2008) Neu-
ropsychiatric symptoms in the community-based patients with
mild cognitive impairment and the influence of demographic
factors. Int J Geriatr Psychiatry 23, 699-703.
[38] Panza F, D’Introno A, Colacicco AM, Capurso C, Del Parigi A,
Caselli RJ, Todarello O, Pellicani V, Santamato A, Scapicchio
P, Maggi S, Scafato E, Gandin C, Capurso A, Solfrizzi V;
Italian Longitudinal Study on Aging Working Group (2008a)
Depressive symptoms, vascular risk factors and mild cognitive
impairment. The Italian longitudinal study on aging. Dement
Geriatr Cogn Disord 25, 336-346.
[39] Panza F, Capurso C, D’Introno A, Colacicco AM, Zenzola A,
Menga R, Pistoia G, Santamato A, Scafato E, Gandin C, Ca-
purso A, Solfrizzi V (2008b) Impact of depressive symptoms
on the rate of progression to dementia in patients affected by
mild cognitive impairment. The Italian Longitudinal Study on
Aging. Int J Geriatr Psychiatry 23, 726-734.
[40] Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Del Parigi
A, Caselli RJ, Scapicchio PL, Scafato E, Gandin C, Capurso
A, Panza F; Italian Longitudinal Study on Aging Working
Group (2007) Incident occurrence of depressive symptoms
among patients with mild cognitive impairment – the Italian
longitudinal study on aging. Dement Geriatr Cogn Disord 24,
55-64.
[41] American Psychiatric Association (1994) Diagnostic and sta-
tistical manual of mental disorders, ed 4. Washington, DC:
American Psychiatric Association.
[42] Andresen EM, Malmgren JA, Carter WB, Patrick DL (1994)
Screening for depression in well older adults: evaluation of a
short form of the CES-D (Center for Epidemiologic Studies
Depression Scale). Am J Prev Med 10, 77–84.
[43] Beck AT, Ward CH, Mendelson M, Mock J, Erbaug J (1961)
An inventory for measuring depression. Arch Gen Psychiatry
4, 561-571.
[44] Montgomery SA, Asberg M (1979) A new depression scale
designed to be sensitive to change. Br J Psychiatry 134, 382–
389.
[45] Yesavage JA (1988) Geriatric Depression Scale. Psychophar-
macol Bull 24, 709–711.
[46] Burns A, Lawlor B, Craig S (2002) Rating scales in old age
psychiatry. Br J Psychiatry 180, 161-167.
[47] Cummings JL, Mega M, Gray K, Rosenberg-Thompson S,
Carusi DA, Gornbein J (1994) The Neuropsychiatric Invento-
ry: comprehensive assessment of psychopathology in demen-
tia. Neurology 44, 2308–2314.
[48] Rabins PV (1994) The validity of a caregiver rated brief Be-
havior Symptom Rating Scale (BSRS) for use in the cogni-
tively impaired. Int J Geriatr Psychiatry 9, 205–210.
[49] Tariot PN (1996) CERAD behavior rating scale for dementia.
Int Psychogeriatr 8 (suppl 3), 317–320.
[50] Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall
G (1978) A comprehensive psychopathological rating scale.
Acta Psychiatr Scand (Suppl) 271, 5-27.
[51] Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma
S, Goddard R. (1986) CAMDEX. A standardised instrument
for the diagnosis of mental disorder in the elderly with special
reference to the early detection of dementia. Br J Psychiatry
149, 698-709.
[52] Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs
J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The
Mini-International Neuropsychiatric Interview (M.I.N.I.): the
development and validation of a structured diagnostic psychi-
atric interview for DSM-IV and ICD-10. J Clin Psychiatry 59
(Suppl 20), 22-33.
[53] Caputo M, Monastero R, Mariani E, Santucci A, Mangialasche
F, Camarda R, Senin U, Mecocci P (2008) Neuropsychiatric
symptoms in 921 elderly subjects with dementia: a compari-
son between vascular and neurodegenerative types. Acta Psy-
chiatr Scand 117, 455-464.
[54] Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens
DC, Breitner JC (2000) Mental and behavioral disturbances in
dementia: findings from the Cache County Study on Memory
in Aging. Am J Psychiatry 157, 708-714.
[55] Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick
D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Fried-
land RP, Bachman D, Farrer L (2003) Depression as a risk fac-
tor for Alzheimer disease: the MIRAGE Study. Arch Neurol
60, 753-759.
30 R. Monastero et al. / A Systematic Review of NPS in MCI
[56] Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D
(2006) Depression and risk for Alzheimer disease: systematic
review, meta-analysis, and metaregression analysis. Arch Gen
Psychiatry 63, 530-538.
[57] Palmer BW, Jeste DV, Sheikh JI (1997) Anxiety disorders
in the elderly: DSM-IV and other barriers to diagnosis and
treatment. J Affect Disord 46, 183-190.
[58] Ropacki SA, Jeste DV (2005) Epidemiology of and risk factors
for psychosis of Alzheimer’s disease: a review of 55 studies
published from 1990 to 2003. Am J Psychiatry 162, 2022-
2030.
[59] Fahn S, Elton RL, Members of the UPDRS Development Com-
mittee (1987) Unified Parkinson’s Disease Rating Scale. In
Recent developments in Parkinson’s disease, Fahn S, Marsden
CD, Calne DB, eds. Florham Park, NJ: Macmillan Healthcare
Information, pp. 153–304.
[60] Starkstein SE, Jorge R, Mizrahi R, Robinson RG (2006) A di-
agnostic formulation for anosognosia in Alzheimer’s disease.
J Neurol Neurosurg Psychiatry 77, 719-725.
[61] Forsell Y, Jorm AF, Winblad B (1994) Association of age, sex,
cognitive dysfunction, and disability with major depressive
symptoms in an elderly sample. Am J Psychiatry 151, 1600-
1604.
[62] Baldwin RC (2007) Recent understandings in geriatric affec-
tive disorder. Curr Opin Psychiatry 20, 539-543.
[63] Lee HB, Lyketsos CG (2003) Depression in Alzheimer’s dis-
ease: heterogeneity and related issues. Biol Psychiatry 54,
353-362.
[64] Ready RE, Ott BR, Grace J (2004) Validity of informant re-
ports about AD and MCI patients’ memory. Alzheimer Dis
Assoc Disord 18, 11-16.
[65] Gomez-Isla T, Hyman BT (2003) Neuropathological changes
in normal aging, minimal cognitive impairment, and
Alzheimer’s disease. In Mild Cognitive Impairment: Aging to
Alzheimer’s Disease, Petersen RC ed. Oxford University Press
Inc, New York, pp. 191-204.
[66] Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM,
Mash DC, McIntyre LM (1998) Neuropathological and neu-
ropsychological changes in “normal” aging: evidence for pre-
clinical Alzheimer disease in cognitively normal individuals.
J Neuropathol Exp Neurol 57, 1168-1174.
[67] Thomas AJ, O’Brien JT (2008) Depression and cognition in
older adults. Curr Opin Psychiatry 21, 8-13.
